Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors?

Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone... Supportive Care in Cancer https://doi.org/10.1007/s00520-018-4301-3 LETTER TO THE EDITOR Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? Kadri Altundag Received: 17 February 2018 /Accepted: 27 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 To the Editor, rates of MRONJ in both control and study arms were I wish to congratulate van Cann and their colleagues [1]in almost similar (10.9 vs. 11.1%, p = 0.95) in the longer which they investigated medication-related osteonecrosis follow-up. of the jaw (MRONJ) incidence in patients exposed con- comitantly to bone resorption inhibitors (BRIs) and vas- Compliance with ethical standards cular endothelial growth factor receptor tyrosine kinase Conflict of interest The author has no conflict of interest. inhibitors (VEGFR-TKIs). They concluded that patients receiving concomitant treatment with VEGFR-TKIs and BRIs have a five to ten times higher risk for development of MRONJ compared to patients treated with BRIs alone. Reference However, 86.7 and of 1.9% of all patients in study group (BRIs + VEGFR-TKIs) and control groups (BRIs only) 1. van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems were diagnosed with renal cell carcinoma, respectively. L et al (2018) Incidence of medication-related osteonecrosis of the Therefore, it is not generalizable to conclude that concom- jaw in patients treated with both bone resorption inhibitors and vas- itant treatment with VEGFR-TKIs and BRIs increase cular endothelial growth factor receptor tyrosine kinase inhibitors. MRONJ incidence in all solid tumors. Actually, incidence Support Care Cancer 26(3):869–878 * Kadri Altundag altundag66@yahoo.com MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Supportive Care in Cancer Springer Journals

Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors?

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/medication-related-osteonecrosis-of-the-jaw-incidence-in-patients-o6TglQrjVn
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine
ISSN
0941-4355
eISSN
1433-7339
D.O.I.
10.1007/s00520-018-4301-3
Publisher site
See Article on Publisher Site

Abstract

Supportive Care in Cancer https://doi.org/10.1007/s00520-018-4301-3 LETTER TO THE EDITOR Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? Kadri Altundag Received: 17 February 2018 /Accepted: 27 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 To the Editor, rates of MRONJ in both control and study arms were I wish to congratulate van Cann and their colleagues [1]in almost similar (10.9 vs. 11.1%, p = 0.95) in the longer which they investigated medication-related osteonecrosis follow-up. of the jaw (MRONJ) incidence in patients exposed con- comitantly to bone resorption inhibitors (BRIs) and vas- Compliance with ethical standards cular endothelial growth factor receptor tyrosine kinase Conflict of interest The author has no conflict of interest. inhibitors (VEGFR-TKIs). They concluded that patients receiving concomitant treatment with VEGFR-TKIs and BRIs have a five to ten times higher risk for development of MRONJ compared to patients treated with BRIs alone. Reference However, 86.7 and of 1.9% of all patients in study group (BRIs + VEGFR-TKIs) and control groups (BRIs only) 1. van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems were diagnosed with renal cell carcinoma, respectively. L et al (2018) Incidence of medication-related osteonecrosis of the Therefore, it is not generalizable to conclude that concom- jaw in patients treated with both bone resorption inhibitors and vas- itant treatment with VEGFR-TKIs and BRIs increase cular endothelial growth factor receptor tyrosine kinase inhibitors. MRONJ incidence in all solid tumors. Actually, incidence Support Care Cancer 26(3):869–878 * Kadri Altundag altundag66@yahoo.com MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800 Ankara, Turkey

Journal

Supportive Care in CancerSpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off